CARTHERai™

CAnceR THErapy Rating Algorithm Infrastructure

OUR MISSION IS TO IDENTIFY THE RIGHT THERAPY FOR EVERY CANCER PATIENT

Revealing secrets beyond the genome

The integration of Multi-Omics with whole genome sequencing, through advances in bioinformatics and AI technology, is now beginning to reveal new actionable insights for allocating cancer treatment.

The database

5410
samples, genomic and other omics data

Whole genome sequencing pipeline

Detection of genomic changes and in-depth analysis

Publication: „Accuracy of somatic variant detection workflows for whole genome sequencing experiments”
Read

Proprietary Biomarker-Auto Search Engine (BASE)

BASE extracts a variety of biomarker classes​ from proprietary database.

Proprietary database

67321
biomarkers

The database includes multiple types of molecular biomarkers (e.g., mutational patterns, CNVs beyond coding regions, somatic structural variations, gene expression).

Biomarker signature

MNM’s extensive tumor database allows for selection of a cohort of responders to a given therapy. Then, ”Biomarker Signature” is defined as a consensus biomarker set allowing to predict the response for new patients. Proprietary AI is used to optimize the biomarker signature.

Publication: “Random Similarity Forests”
Read

Patient stratification

Biomarker signature is a tool ready for patient stratification and can be developed into a diagnostic test.

Competitive advantage

Comprehensive infrastructure for whole genome sequencing data

Cloud-based bioinformatic solutions
Proprietary data infrastructure
Custom AI-driven platform for genomic data mining
Search for multilevel biomarker interdependencies for predictive and prognostic models

Biomarker signature discovery

for every cancer therapy

Complete genomic information beyond standards
Pathway deconvolution

Any questions?

Contact us

Contact page